Oceva 10mg/ml Injection contains Ranibizumab, a recombinant humanized monoclonal antibody fragment specifically designed to inhibit vascular endothelial growth factor A (VEGF-A). It is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), macular edema following retinal vein occlusion (RVO), and other retinal vascular disorders characterized by abnormal angiogenesis and increased vascular permeability. Ranibizumab acts by binding to VEGF-A isoforms, thereby preventing their interaction with VEGF receptors on the surface of endothelial cells, which results in the inhibition of pathological neovascularization and reduction of vascular leakage. Oceva is administered via intravitreal injection, typically at a dose of 0.5 mg (0.05 ml) per injection, with dosing frequency determined by the treating ophthalmologist based on disease severity and response. Clinical studies have demonstrated its efficacy in improving visual acuity and reducing retinal thickness in affected patients. Common adverse effects include conjunctival hemorrhage, eye pain, vitreous floaters, and increased intraocular pressure. Proper aseptic technique and patient monitoring are essential to minimize the risk of endophthalmitis and other injection-related complications. Oceva should be used under specialist supervision with regular ophthalmic evaluations to optimize therapeutic outcomes.